Certain holders agreed to exercise Outlook Therapeutics warrants at a reduced exercise price while receiving new warrants 

Davis Polk advised the capital markets adviser in connection with Outlook Therapeutics, Inc.’s  agreements with certain holders of existing warrants to purchase Outlook Therapeutics common stock, exercisable for an aggregate of 8,146,066 shares of common stock, pursuant to which the holders agreed to exercise their existing warrants at a reduced exercise price of $2.51 per share, in exchange for Outlook Therapeutics’ agreement to issue, for each existing warrant being exercised, two new warrants to purchase common stock.

Outlook Therapeutics will use the proceeds from the transaction to fund its ONS-5010 clinical development programs, European commercial launch of LYTENAVA and for working capital and general corporate purposes.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA, for the treatment of retina diseases, including wet AMD.

The Davis Polk corporate team included partner Derek Dostal and associate Marcos Sauquet Trias. All members of the Davis Polk team are based in the New York office.

Copy link to share post